| Pre-IPTW | Post-IPTW‡ | |||||
|---|---|---|---|---|---|---|
| Warfarin cohort (ref) | Apixaban cohort | STD† | Warfarin cohort (ref) | Apixaban cohort | STD† | |
| Sample size | 12,918 | 13,604 | 12,918 | 13,604 | ||
| Age (years), mean (SD) | 74.4 (7.9) | 75.4 (7.6) | 12.6 | 74.9 (7.9) | 74.9 (7.6) | 0.0 |
| Age category (years), n (%) | ||||||
| 18-54 | 96 (1) | 62 (0) | 3.7 | 80 (1) | 77 (1) | 0.6 |
| 55-64 | 780 (6) | 482 (4) | 11.7 | 688 (5) | 548 (4) | 6.2 |
| 65-74 | 6434 (50) | 6722 (49) | 0.8 | 6196 (48) | 6960 (51) | 6.4 |
| 75-79 | 2231 (17) | 2420 (18) | 1.4 | 2286 (18) | 2375 (18) | 0.6 |
| ≥80 | 3377 (26) | 3918 (29) | 6.0 | 3669 (28) | 3644 (27) | 3.6 |
| Gender, n (%) | ||||||
| Men | 12,739 (99) | 13,430 (99) | 0.9 | 12,745 (99) | 13,423 (99) | 0.1 |
| Women | 179 (1) | 174 (1) | 0.9 | 173 (1) | 181 (1) | 0.1 |
| Race, n (%) | ||||||
| White | 11,820 (92) | 12,473 (92) | 0.7 | 11,835 (92) | 12,462 (92) | 0.0 |
| Black | 801 (6) | 791 (6) | 1.6 | 771 (6) | 814 (6) | 0.0 |
| Other | 191 (1) | 229 (2) | 1.6 | 205 (2) | 215 (2) | 0.1 |
| Unknown | 106 (1) | 111 (1) | 0.1 | 107 (1) | 113 (1) | 0.1 |
Please use landscape view or desktop screen to view the content.
Pre-IPTW and Post-IPTW Baseline Characteristics Among Obese* NVAF Patients Initiating Apixaban Versus Warfarin
Deitelzweig VA and Medicare 2022
